High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib

Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC)....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhang Ying, Zhang Xiaowen, Wang Fang, Feng Yan, Tang Huaping
Formato: article
Lenguaje:EN
Publicado: De Gruyter 2021
Materias:
R
Acceso en línea:https://doaj.org/article/b6e0ac2177964adead41d36295725fc0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Brain metastases (BMs) and bone metastases seriously affect the prognosis of lung cancer patients. How to optimize the use of existing targeted drugs is an important way to address the clinical needs of the central nervous system in the individualized treatment of non-small cell lung cancer (NSCLC). In this report, we describe an NSCLC patient with BMs who survived for 58 months, which is the longest survival case among lung cancer patients with BMs. The patient was initially diagnosed with lung cancer more than 5 years ago with simultaneous brain, bone, and lung metastases. After gefitinib resistance, she received osimertinib in sequence with no progress for 58 months in total and maintained very good quality of life.